Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ( " Theravance Biopharma " ) and Mylan N.V. (NASDAQ, TASE: MYL) ( " Mylan " ) today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news